Patents by Inventor Xiaohua He
Xiaohua He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250363668Abstract: An embodiment of the present disclosure provides a signal analysis interaction method, a signal analysis apparatus, an electronic device, and a computer-readable storage medium. The method includes displaying a signal analysis item configuration interface in the screen; obtaining a first control operation via the signal analysis item configuration interface to determine one or more analysis items to be performed; displaying a waveform image of at least one obtained signal according to the obtained signal; displaying a selection area in response to a second control operation, where the selection area is configured to indicate an area selected through the second control operation; obtaining a parameter of a signal selected through the second control operation according to an image in the selection area; and performing the one or more analysis items to be performed according to the parameter of the signal and displaying a performing result.Type: ApplicationFiled: August 8, 2025Publication date: November 27, 2025Inventors: Xiaohua HE, Yue WANG
-
Publication number: 20250304660Abstract: The disclosure relates to humanized antibodies (Hu mAb) or antigen-binding fragments thereof that bind to or recognize Shiga toxin (Stx)2, compositions comprising such antibodies or antigen-binding fragments, methods comprising such antibodies or antigen-binding fragments, and methods of using such antibodies or antigen-binding fragments. The Hu mAb or antigen binding fragments thereof that bind to or recognize Stx2 may be used for treating a subject in need thereof to prevent or ameliorate one or more symptoms of Shiga toxin-producing Escherichia coli (STEC) infection in the subject, or to prevent or ameliorate one or more symptoms of hemolytic uremic syndrome (HUS) in the subject.Type: ApplicationFiled: April 19, 2024Publication date: October 2, 2025Inventors: XIAOHUA HE, ANNA C. HUGHES, MARINA E. KIRKLAND MITCHELL
-
Patent number: 12323508Abstract: The present application relates to an electronic test equipment and an optional function configuring method. A ciphertext decryption authentication unit performs a decryption authentication operation according to a function option key and a function option ciphertext, performs a corresponding operation on a function device corresponding to the function option ciphertext according to an authentication result signal, and outputs the authentication result signal to an operation control unit, such that the operation control unit operates, according to the authentication result signal, a target function corresponding to the function option ciphertext.Type: GrantFiled: May 16, 2023Date of Patent: June 3, 2025Assignee: RIGOL TECHNOLOGIES CO., LTD.Inventors: Xiaohua He, Yue Wang
-
Publication number: 20250077045Abstract: An embodiment of the present disclosure relates to a signal analysis interaction method and a signal analysis apparatus. The method may include displaying an image of at least one waveform of an obtained signal in an image display area of a screen according to the signal; displaying a selection area in the image display area in response to a first control operation, wherein the selection area is configured to indicate an area selected by the first control operation in the image display area; determining a channel list of the signal selected by the first control operation according to an image in the selection area; and displaying a function option to be executed according to the channel list.Type: ApplicationFiled: October 30, 2024Publication date: March 6, 2025Applicant: RIGOL TECHNOLOGIES CO., LTD.Inventors: Xiaohua HE, Yue WANG
-
Publication number: 20230291543Abstract: The present application relates to an electronic test equipment and an optional function configuring method. A ciphertext decryption authentication unit performs a decryption authentication operation according to a function option key and a function option ciphertext, performs a corresponding operation on a function device corresponding to the function option ciphertext according to an authentication result signal, and outputs the authentication result signal to an operation control unit, such that the operation control unit operates, according to the authentication result signal, a target function corresponding to the function option ciphertext.Type: ApplicationFiled: May 16, 2023Publication date: September 14, 2023Applicant: RIGOL TECHNOLOGIES CO., LTD.Inventors: Xiaohua HE, Yue WANG
-
Patent number: 11161896Abstract: Monoclonal antibodies against bacterial proteins that confer resistance to the antibiotic colistin and hybridomas that produce such monoclonal antibodies are described. The monoclonal antibodies have a strong affinity for MCR proteins and may be used in detection methods and kits to detect the presence of MCR proteins including variants thereof in a sample.Type: GrantFiled: March 14, 2019Date of Patent: November 2, 2021Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Xiaohua He, Daniela Mavrici
-
Publication number: 20190322727Abstract: Monoclonal antibodies against bacterial proteins that confer resistance to the antibiotic colistin and hybridomas that produce such monoclonal antibodies are described. The monoclonal antibodies have a strong affinity for MCR proteins and may be used in detection methods and kits to detect the presence of MCR proteins including variants thereof in a sample.Type: ApplicationFiled: March 14, 2019Publication date: October 24, 2019Inventors: Xiaohua He, Daniela Mavrici
-
Patent number: 9513287Abstract: High affinity monoclonal antibodies against Stx2f and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting Stx2f and variants thereof in a sample as well as neutralization of Shiga toxin in vivo.Type: GrantFiled: May 9, 2014Date of Patent: December 6, 2016Assignee: The United States of America, as represented by The Secretary of AgricultureInventors: Xiaohua He, Larry H. Stanker, Craig B. Skinner
-
Patent number: 9310368Abstract: High affinity monoclonal antibodies against Stx2 and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting Stx2 and variants thereof in a sample as well as neutralization of Shiga toxin in vivo.Type: GrantFiled: September 27, 2013Date of Patent: April 12, 2016Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Xiaohua He, Larry H. Stanker, Luisa W. Cheng
-
Publication number: 20120260298Abstract: The present invention provides method and system for sharing video among mobile terminals. The method comprises: a calling terminal uploads a video file to a media server; a called terminal establishes a video link with the media server through a mobile network; the media server sends a video stream to the called terminal through the video link; the called terminal receives the video stream from the media server and plays the video file. The method and system provided by the present invention enable simultaneous sharing of the same video among multiple called terminals and enable a called terminal to watch the same shared video multiple times, therefore not only time and labour are saved, but also user experience is enhanced. By playing shared video through a mobile network, stream media is played directly and more smoothly, and problems of video buffering and video stagnating in video sharing are solved.Type: ApplicationFiled: June 11, 2010Publication date: October 11, 2012Applicant: ZTE CORPORATIONInventors: Xi Chen, Guanwei Tian, Yabin Li, Xiaohua He, Chengcan Wang
-
Patent number: 7211671Abstract: The present invention describes novel 1,3-dihydro-imidazol-2-one or 1,3-dihydro-imidazol-2-thione compounds of formula (I): or a stereoisomer or pharmaceutically acceptable salt or solvate thereof, wherein A, L R1, R2, R3 and R4 are defined in the present specification, which are useful as selective inhibitors of MMP, TACE, aggrecanase or a combination thereof. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.Type: GrantFiled: September 21, 2004Date of Patent: May 1, 2007Assignee: Bristol Myers Squibb CompanyInventors: James Sheppeck, John L. Gilmore, Xiao-Tao Chen, Xiaohua He
-
Patent number: 7195901Abstract: The gene for the diacylglycerol acyltransferase (DGAT) from Ricinus communis L., the castor plant, has been isolated, cloned, and used to transform other plants and micro-organisms. When the gene is expressed in a heterologous system, the corresponding DGAT protein is active and shows unusual and selective action for hydroxylated fatty acyl glycerides. DGAT carries out the final step in castor oil biosynthesis, and is believed to be largely responsible for many of the attributes of castor oil, making it an excellent candidate for industrial uses. This invention makes it possible to enhance the oil-producing capacity of other plants and micro-organisms.Type: GrantFiled: June 3, 2004Date of Patent: March 27, 2007Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Thomas A. McKeon, Xiaohua He, Jiann-Tsyh Lin
-
Patent number: 6858626Abstract: The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.Type: GrantFiled: June 20, 2002Date of Patent: February 22, 2005Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Chu-Biao Xue, Carl P. Decicco, Xiaohua He
-
Patent number: 6642255Abstract: The present application describes novel 1,2-disubsituted cyclic derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-8 membered non-aromatic ring consisting of: carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring heteroatoms selected from O, N, NR2, and S(O)p and the other variables are defined in the present specification, which are useful as metalloprotease and as TNF-&agr; inhibitors.Type: GrantFiled: January 9, 2002Date of Patent: November 4, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Chu-Biao Xue, Carl Decicco, Xiaohua He
-
Publication number: 20030139597Abstract: The present application describes novel cyclic hydroxamic acids of formula I: 1Type: ApplicationFiled: June 20, 2002Publication date: July 24, 2003Inventors: Chu-Biao Xue, Carl P. Decicco, Xiaohua He
-
Publication number: 20030087890Abstract: The present application describes novel 1,2-disubsituted cyclic derivatives of formula I: 1Type: ApplicationFiled: January 9, 2002Publication date: May 8, 2003Inventors: Chu-Biao Xue, Carl Decicco, Xiaohua He
-
Patent number: 6429213Abstract: The present application de gibes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.Type: GrantFiled: June 17, 1999Date of Patent: August 6, 2002Inventors: Chu-Biao Xue, Carl P. Decicco, Xiaohua He
-
Patent number: 6281352Abstract: This invention relates to macrocyclic molecules which inhibit metalloproteinases, including aggrecanase, and the production of tumor necrosis factor (TNF). In particular, the compounds are inhibitors of metalloproteinases involved in tissue degradation and inhibitors of the release of tumor necrosis factor. The present invention also relates to pharmaceutical compositions comprising such compounds and to methods of using these compounds for the treatment of inflammatory diseases.Type: GrantFiled: May 14, 1997Date of Patent: August 28, 2001Assignee: DuPont Pharmaceuticals CompanyInventors: Chu-Bio Xue, Carl P. Decicco, Robert J. Cherney, Elizabeth Arner, William F. DeGrado, Jingwu Duan, Xiaohua He, Irina Cipora Jacobson, Ronald L. Magolda, David Nelson
-
Patent number: 5347040Abstract: Onium salt capable of generating acid upon exposure to actinic radiation having the following structure:(R.sub.1).sub.a (R.sub.2).sub.b (R.sub.3).sub.c Q.sup.+ --A--M.sup.+ X.sup.- --B--X'.sup.-where:Q is S;R.sub.1, R.sub.2 and R.sub.3 are independently substituted or unsubstituted aromatic, aliphatic, or aralkyl groups having 7-18 carbon atoms;M.sup.+ is a cationic organic radical;A is a divalent radical selected from the group of hindered alkylene groups, substituted or unsubstituted aromatic or aralkyl groups;B is a divalent aromatic sensitizer which absorbs radiation having a wavelength longer than 300 nm and is capable of transferring an electron to Q,x.sup.- and X'.sup.- are anionic groups; and wherein A provides a spatial separation between Q and M, and B provides a spatial separation between X and X', such that the spatial separation provided by A between Q and M is substantially the same as the spatial separation provided by B between X and X'.Type: GrantFiled: December 9, 1992Date of Patent: September 13, 1994Assignee: E. I. Du Pont de Nemours and CompanyInventors: Arnost Reiser, Xiaohua He